All In Biotech

Drug Trial Radar · NCT05072080

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,258 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,258

Actual

Start

Sep 29, 2021

Primary completion

Apr 3, 2023

Study completion Apr 3, 2023

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Emergent BioSolutions
First posted
Oct 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.

Conditions

  • Chikungunya Virus

Interventions

  • CHIKV VLP/adjuvantBiological

    CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%

  • PlaceboBiological

    Placebo is comprised of formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Solicited Adverse Events (AE)Time frame: 7 days post-vaccination
  2. Incidence of Unsolicited AEsTime frame: 28 days post-vaccination
  3. Incidence of Adverse Events of Special Interest (AESI)Time frame: 182 days post-vaccination
  4. Incidence of Medically Attended Adverse Event (MAAE)Time frame: 182 days post-vaccination
  5. Incidence of Serious Adverse Event (SAE)Time frame: 182 days post-vaccination
  6. Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22Time frame: 21 days post-vaccination
  7. Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22 (Data Reported Per Arm)Time frame: 21 days post-vaccination
  8. Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22Time frame: 21 days post-vaccination
  9. Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - All Age Strata)Time frame: 21 days post-vaccination
  10. Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (for Lot Comparison)Time frame: 21 days post-vaccination
  11. Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - Adults 18 to <46)Time frame: 21 days post-vaccination

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • Optimal Research, LLC

    Huntsville, Alabama

  • Alliance for Multispecialty Research - Mobile

    Mobile, Alabama

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona

  • Velocity Clinical Research, Banning

    Banning, California

  • Optimal Research, LLC

    San Diego, California

  • Lynn Institute of the Rockies

    Colorado Springs, Colorado

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Accel Research Sites-DeLand Clinical Research Unit

    Lake Mary, Florida

  • Optimal Research, LLC

    Melbourne, Florida

  • Suncoast Research Associates, LLC

    Miami, Florida

  • Synexus Clinical Research US, Inc.

    Pinellas Park, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Velocity Clinical Research, Boise

    Meridian, Idaho

  • Synexus Clinical Research US, Inc.

    Chicago, Illinois

  • Optimal Research LLC

    Peoria, Illinois

  • Johnson County ClinTrials

    Lenexa, Kansas

  • Alliance for Multispecialty Research, LLC

    Newton, Kansas

  • Alliance for Multispecialty Research - Wichita East

    Wichita, Kansas

  • Alliance for Multispecialty Research, LLC

    Lexington, Kentucky

  • Alliance for Multispecialty Research, LLC

    New Orleans, Louisiana

  • Optimal Research, LLC

    Rockville, Maryland

  • Alliance for Multispecialty Research - Kansas City

    Kansas City, Missouri

  • Saint Louis University

    St Louis, Missouri

  • Synexus Clinical Research US, Inc.

    St Louis, Missouri

  • Wr-Crcn, Llc

    Las Vegas, Nevada

  • Alliance for Multispecialty Research, LLC.

    Las Vegas, Nevada

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • M3 Wake Research, Inc

    Raleigh, North Carolina

  • Trial Management Associates, LLC

    Wilmington, North Carolina

  • Cincinnati Children's Hospital Medical Center - The Gamble Vaccine Research Center

    Cincinnati, Ohio

  • Velocity Clinical Rsearch, Inc.

    Cleveland, Ohio

  • Aventiv Research Inc.

    Columbus, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Velocity Clinical Research, Medford

    Medford, Oregon

  • Velocity Clinical Research-Providence

    East Greenwich, Rhode Island

  • Synexus Clinical Research US, Inc.

    Anderson, South Carolina

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Alliance for Multispecialty Research, LLC

    Knoxville, Tennessee

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.